Research company Stayble Therapeutics has provided an update regarding its intellectual property assets.
As of today, the company holds patent protection directly linked to STA363 for the treatment of herniated discs in a total of 32 countries, with all but South Africa located in Europe. According to a press release, these protections are valid until December 17, 2041.
"Having approved patents in a large number of countries is an important piece of the puzzle for our future development. It strengthens our commercial protection and our position ahead of upcoming partnerships and the commercialization of STA363," said Andreas Gerward, CEO of Stayble Therapeutics.
The company also has ongoing patent applications in the United States, Japan, China, and Australia.